Related Experiment Videos
Morphometric prognostic index in breast cancer
A Carbone1, F G Serra, A Rinelli
1Institutes of Pathological Anatomy, Catholic University of the Sacred Heart, Rome, Italy.
Analytical and Quantitative Cytology and Histology
|November 24, 1999
Summary
The morphometric prognostic index (MPI) effectively predicts breast cancer outcomes, even with short follow-up. This reliable and economical prognosticator aids in selecting patients for adjuvant chemotherapy.
Area of Science:
- Oncology
- Pathology
Background:
- Accurate prognostic markers are crucial for breast cancer management.
- The morphometric prognostic index (MPI) is a potential tool for predicting clinical outcomes.
Purpose of the Study:
- To evaluate the predictive ability of MPI for clinical outcomes in breast cancer patients.
- To examine the relationship between MPI and other established prognostic factors.
Main Methods:
- Calculated MPI values for 48 breast cancer patients with available follow-up data.
- Assessed nuclear and tubular differentiation, S-phase fraction (SPF), and estrogen/progesterone receptor status.
- Correlated MPI with clinical outcomes and other prognosticators.
Main Results:
- Patients with MPI < 0.60 demonstrated significantly higher disease-free survival rates.
- MPI showed direct correlations with nuclear atypia and SPF.
- MPI exhibited inverse relationships with progesterone receptor levels and histologic tubular differentiation.
Conclusions:
- The morphometric prognostic index (MPI) is a valid prognosticator in breast cancer, even with short-term follow-up.
- MPI serves as a reliable and economical tool for selecting breast cancer patients for adjuvant chemotherapy.